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Human herpesvirus 6 (HHV-6) is a lymphotropic herpesvirus, and in vitro, HHV-6 can productively infect 
many of the same cell types as can human immunodeficiency virus (HIV). Coinfection by both viruses in vitro 
can lead to both activation of the HIV promoter and acceleration of cytopathic effects. We have previously 
demonstrated that a large, 22.25-kb cloned HHV-6 fragment, pZVB70, can trans activate HIV promoter 
expression in vitro. In this study, we show that the pZVB70 fragment can trans activate the HIV promoter in 
human T-cell lines as well as in the monkey kidney cell line CV-1. The pZVB70 insert was digested with various 
restriction enzymes, and individual fragments were transfected into cells to test for their ability to trans activate 
the HIV promoter. By this method, we have identified a 1.8-kb subfragment, B701, that is involved in trans 
activation. Sequence analyses show that B701 potentially encodes a 143-amino-acid protein. This protein shares 
no homology with other herpesvirus proteins, such as ICPO and ICP4, that have been shown to trans activate 
the HIV promoter. However, it shows weak sequence homology with the gene products encoded by the 
cytomegalovirus early US22 gene family, suggesting that the putative B701 protein may be an HHV-6 early 
regulatory protein. The 143-amino-acid coding sequence of B701 was cloned by polymerase chain reaction, and 
transfection of this construct into cells activated HIV promoter expression. The target site on the HIV promoter 
for the putative B701 protein is mapped to the NF-KB binding site. Our results suggest that the putative B701 
protein may function by directly binding to the NF-KB site or may involve cellular factors, such as NF-KB, 
either directly or indirectly. 
Human immunodeficiency virus (HIV) is the etiologic 
agent for AIDS. Infection by HIV can lead to either acute or 
chronic infections, and activation signals are necessary to 
establish a productive infection (8). Latent infection can 
persist for years after the initial HIV infection, which can be 
stimulated into acute phase by various cofactors (3). These 
cofactors probably play a very important role in the patho- 
genesis of HIV infection and in the clinical manifestation of 
AIDS. These cofactors could be of nonviral origin, such as 
lymphokines (9), mitogens, or antigens (12, 33). In addition, 
exogenous viral infection, such as by herpes simplex virus 
(HSV) (22, 23), adenovirus (28), and hepatitis B virus (31), 
have all been demonstrated to stimulate HIV replication in 
vitro. It has also been shown that viral infections can lead to 
the activation of HIV long terminal repeat (LTR)-directed 
viral gene expression (10, 22, 32). The mechanism of activa- 
tion is not completely clear, but it may involve viral gene 
products, such as the immediate-early gene products of 
HSV-1 (1) and cytomegalovirus (6). It is possible that these 
viral gene products interact directly with the HIV LTR, or 
indirectly via cellular factors such as NF-KB, in the trans 
activation of HIV (10). 
Among the herpesviruses that have been shown to trans 
activate HIV expression, the newly identified Human her- 
pesvirus 6 (HHV-6) seems to be most interesting. HHVd 
has been isolated from AIDS patients (30, 3 9 ,  from patients 
with lymphoproliferative disorders (30), and from children 
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with exanthem subitum (34). HHV-6 infection among hu- 
mans is very common, and most individuals are seropositive 
for HHV-6 (15). In vitro, HHV-6 can productively infect 
many of the same cell types as can HIV, particularly CD4+ 
human T cells, and coinfection of T cells with HIV and 
HHV-6 leads to accelerated cytopathic effects (20). Re- 
cently, it has been shown that infection of CD8+ cells by 
HHV-6 leads to surface expression of the CD4 molecule, 
thus rendering these cells susceptible to HIV infection (21). 
In contrast, other recent studies demonstrated that coinfec- 
tion of peripheral blood mononuclear cells with HHV-6 and 
HIV suppressed HIV replication (4, 18). The differences 
between these studies may be due to the nature of the cells 
that were infected, dosage of virus used, and the time of 
infection. Therefore, it is important to isolate the specific 
HHVd genes that may be involved in either activation or 
suppression of HIV. 
We have demonstrated previously that in vitro infection 
with HHVd strains GS and 2-29 can activate HIV LTR 
expression in human T-cell lines (13) and in a heterogeneous 
population of antigen-specific primary human T lymphocytes 
(14). Activation of the HIV LTR by HHV-6 in normal human 
T lymphocytes potentially reflects an in vivo situation, 
where there may be additive effects on trans activation by 
HHVd and stimulation with specific antigen. Taken to- 
gether, these results suggest that HHV-6 can potentially play 
an important role in vivo as a cofactor in HIV infection and 
development of AIDS. 
To gain further insight into the mechanism of HHV-6 trans 
activation of the HIV LTR, it is important to identify the 
HHV-6 gene(s) that is involved. The genome of HHV-6 is 
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about 170 kb in size, and very little is known about the 
identities and functions of its gene products (16). We have 
previously demonstrated that a 22.25-kb H H V d  (GS) gene 
segment (pZVB70) can trans activate the HIV LTR after 
cotransfection into human T-cell lines (14). Here we report 
the identification and characterization of a 1.8-kb gene 
segment from the 22.25-kb pZVB70 fragment that can trans 
activate the HIV LTR. Sequence analyses show that the 
putative trans-acting protein is 143 amino acids in size and 
shares no homology with other herpesvirus gene products 
shown to trans activate the HIV LTR. 
MATERIALS AND METHODS 
Cell l i e s .  The human T-cell line HSB-2 (ATCC CCL 
120.1) and the African green monkey kidney cell line CV-1 
(ATCC CCL 70) were used. T cells were maintained in 
RPMI 1640 medium supplemented with 10% fetal calf serum, 
while CV-1 cells were maintained in Dulbecco modified 
Eagle medium with 10% fetal calf serum. 
DNA and plasmids. Construction of various HIV-chloram- 
phenicol acetyltransferase (CAT) plasmids was previously 
described in detail (17). Briefly, the HIV-CAT construct 
contains both the 3' untranslated regions and the repeat 
sequences of the HIV LTR ligated to the CAT gene. The 
-29 CAT plasmid was constructed by deleting all regulatory 
elements on the HIV LTR except for the TATA box and the 
TAR region. The -57 CAT plasmid was kindly provided by 
Joseph Sodroski (Harvard Medical School, Boston, Mass.) 
(29). The -147 CAT plasmid was constructed by deleting a 
fragment of the HIV LTR at the AvaI site as described 
elsewhere (12). The HIV LTR plasmid containing the mu- 
tated NF-KB site was kindly provided by Gary Nabel (24). 
Construction of HHV-6 pZVB70 and pZVB9 plasmids con- 
taining BamHI fragments of the HHV-6 genome was de- 
scribed previously (14). 
Transfections. HSB-2 cells were transfected by the DEAE- 
dextran method (2). Briefly, 1 pg of DNA, suspended in 700 
pg of DEAE-dextran per ml, was added to HSB-2 cells. 
Cells were then incubated for 2 h at 37°C. The cells were 
then treated with dimethyl sulfoxide (1%) for exactly 90 s. 
After being washed with RPMI 1640 without serum, the cells 
were placed in fresh RPMI 1640 medium containing 10% 
fetal calf serum. Two days later, the transfected cells were 
harvested, washed twice with phosphate-buffered saline 
(PBS), and then used for CAT assays. 
CV-1 cells were transfected by using standard calcium 
phosphate precipitation procedures (11). Briefly, 0.5 x lo6 to 
1 x lo6 cells were incubated with 2 pg of plasmid DNA 
suspended in calcium phosphate for 8 h and then treated with 
15% glycerol for 3 min. Cells were then washed with PBS 
and cultured in fresh medium. After 2 days, transfected cells 
were harvested for CAT assays. 
CAT assays. CAT assays were performed by using 
r3H]acetyl coenzyme A ([3H]acetyl-CoA). Harvested cells 
were resuspended in 100 p1 of sonication buffer (0.25 M 
Tris-HC1, pH 7.8). Cellular extracts were prepared by 
freeze-thawing once, sonicating for 1 min, and briefly cen- 
trifuging to pellet cell debris. HSB-2 cell lysates were used 
for CAT assay directly, whereas CV-1 cell lysates were heat 
treated at 65°C for 5 min before CAT analysis. Protein 
concentrations for each sample were determined by the BCA 
protein assay (Pierce Chemical Co.). All samples were 
corrected for protein concentration variations before use in 
CAT assays. h-ocedures for the CAT assay using [3H]acetyl- 
CoA were previously described (25). Briefly, 50 p1 of cell 
lysate was mixed with 200 p1 of reaction mixture (130 p1 of 
Tris-HCI [pH 7.8],50 p1 of 50 mM chloramphenicol, 1 pCi of 
[3Hlacetyl-Co~, 19 p1 of 4 mM acetyl-CoA). Samples were 
then overlaid with organic scintillation fluid and incubated at 
37°C; counts were taken at 0, 1, 2, 3, 4, and 5 h after 
initiation of the assay. Units of CAT activity for each lysate 
were calculated by extrapolation according to a standard 
curve established with known CAT enzymatic activities. 
DNA sequencing and analysis. DNA sequence analyses 
were performed by the Sequenase (U.S. Biochemical Corp., 
Cleveland, Ohio) method. Sequence data were analyzed by 
using the SAP program (Universal Biotechnology, Inc., 
Rockville, Md.) and by the IBI-Pustell sequence analysis 
program. Amino acid homology analysis was conducted by 
using the FASTA program developed by Lipman and Pear- 
son (19). 
Nucleotide sequence accession number. The sequence data 
presented in this report have been submitted to the GenBank 
and EMBL data bases under accession number M81789. 
RESULTS 
HHVd (GS) genomic fragment (pZVB70) can trans activate 
the HIV LTR in CV-1 cells. We have demonstrated previ- 
ously that the HIV LTR can be trans activated by HHV-6 
infection in human T-cell lines and in primary human T cells. 
Furthermore, the 22.25-kb (pZVB70) HHV-6 genomic seg- 
ment was shown to trans activate the HIV LTR when 
cotransfected into human T cells (14). To determine whether 
HHV-6 trans activation of the HIV LTR is cell type specific, 
similar transfection studies were carried out in CV-1 cells. 
These cells were chosen since various studies, including our 
own, have shown that CV-1 cells can be consistently trans- 
fected with the plasmid containing the HIV LTR and provide 
a good system with which to study trans activation of the 
HIV LTR by various cofactors (27). CV-1 cells were co- 
transfected with HIV-CAT and pZVB70 DNA by the cal- 
cium phosphate precipitation method. At 48 h after transfec- 
tion, cells were harvested and CAT activity was measured. 
All CAT assays were done with [3H]acetyl-CoA because this 
method is quantitative, reproducible, and convenient (25). 
Assays were carried out for 5 h, and CAT activities were 
measured hourly (Fig. 1). Increases in CAT activity were 
calculated by using a standard curve of known units of CAT 
enzymatic activities. Cotransfection of HIV-CAT with 
pZVB70 resulted in a more than 10-fold increase in CAT 
activity, and the trans activation was very consistent. For a 
negative control, other cloned HHV-6 gene segments were 
cotransfected into CV-1 cells along with HIV-CAT. Figure 1 
shows the results of such a study using the 11.8-kb fragment 
(pZVB9). No trans activation of the HIV LTR was observed 
with this or other control fragments. These data demonstrate 
that the trans activation of the HIV LTR by the HHV-6 
DNA fragment pZVB70 is not just T-cell specific. 
A functional NF-KB enhancer element is necessary for Pans 
activation of the HIV LTR by pZVB70 in CV-1 cells. We have 
previously demonstrated that trans activation of the HIV 
LTR by HHV-6 (GS) and the pZVB70 fragment is dependent 
on the presence of a functional NF-KB sequence, since an 
NF-KB mutant promoter was not trans activated by HHV-6 
(13,14). To study the effects of the enhancer element on the 
HIV LTR and to determine whether trans activation of 
HIV-CAT by pZVB70 in CV-1 cells also involves NF-KB, 
transfection studies were carried out by using various HIV 
promoter constructs (Fig. 2). Different constructs of the HIV 
LTR were cotransfected along with pZVB70 into CV-1 cells 
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FIG. 1. CAT enzymatic activity in CV-1 cells. CV-1 cells were 
either transfected with HIV-CAT alone or cotransfected with HIV- 
CAT and different HHV-6 plasmids. CAT activities were quanti- 
tated by using ['Hlacetyl-CoA, and incorporated radioactivities 
were counted hourly. Data represent the means of at least three 
independent experiments. 
(Fig. 3). The promoter constructs -29 CAT and -57 CAT, 
containing deleted NF-KB binding regions, lost their ability 
to be trans activated by pZVB70. Within the -147 CAT 
promoter construct, only the negative regulatory element 
has been deleted, and this construct can still be trans 
activated by pZVB70. The levels of activation were similar 
to those of the intact HIV-CAT. These results thus suggest 
that the target sequence may be located within the NF-KB 
region. This possibility was further confirmed when an 
1-1 -29 CAT 
-57 +80 
-1 47 CAT 
-1 47 +80 




FIG. 2. Schematic diagram of various deleted HIV LTR-CAT 
constructs used in transfection studies. The -29 CAT plasmid 
represents a deletion of all upstream elements up to the TATA box. 
The -57 CAT plasmid contains only one Spl site and the TATA 
box. The -147 CAT plasmid contains the NF-KB site, the Spl sites, 
the TATA box, and the tat target region; it has lost the negative 
regulatory element (NEG reg). The mutant NF-KB promoter con- 
tains mutations in the NF-KB regions (GGG changed to TCT). Intact 
HIV CAT represents the wild-type HIV LTR. RV, EcoRV. 
LTR- In tact  -29 - 5 7  -147  NF-kB 
pZVB70 - + - + - + - + - + 
FIG. 3. CAT activities in CV-1 cells that were transfected with 
various deleted HIV-CAT constructs (as described in the legend to 
Fig. 2) either in the presence or in the absence of pZVB70. 
NF-KB mutant promoter was cotransfected along with 
pZVB70. This mutant promoter contains substitutions 
within each of the core enhancer elements which were 
implicated in binding of cellular NF-KB. These substitutions 
eliminated activation of the HIV promoter by the NF-KB 
protein (24). trans activation by pZVB70 in CV-1 cells was 
completely abolished when the NF-KB mutant promoter was 
used. These results suggest that the NF-KB sequence must 
be involved in trans activation by pZVB70 in CV-1 cells, 
similar to the results obtained earlier in human T cells (7, 13, 
14). 
Identification of a 3.8-kb fragment of pZVB70 which pos- 
sesses trans activation function. The pZVB70 clone contains a 
22.25-kb insert. Hence, it is necessary to further identify and 
characterize the specific gene(s) involved in trans activation. 
Various restriction enzymes were used to cut the pZVB70 
DNA. The digested DNA were then transfected, along with 
HIV-CAT, into CV-1 cells and the human T-cell line HSB-2 
to determine whether they have retained their trans-activat- 
ing functions. Most restriction enzymes used eliminated the 
trans-activation function of pZVB70. However, digestion 
with several enzymes, such as SalI, did not affect its 
activity. Digestion of the pZVB70 22.25-kb insert by Sun 
gave five different smaller fragments of 1.16, 3.0, 3.8, 6.0, 
and 8.2 kb in size. The SalI restriction enzyme-cut sites of 
pZVB70 are shown schematically in Fig. 4A. When each 
SalI fragment was purified and cotransfected individually 
into CV-1 cells along with HIV-CAT to test for trans 
activation, only the 3.8-kb fragment trans activated HIV- 
CAT (Fig. 4B). The trans-activation level of the purified 
3.8-kb fragment is slightly lower than that of intact pZVB70 
(Fig. 4B). This difference may be due to differences in 
efficiency of transfection. Nevertheless, our results indicate 
that the 3.8-kb fragment contains the gene(s) responsible for 
the majority of the trans-activation activities observed with 
the pZVB70 fragment. 
Sequence analyses of the 3.8-kb fragment. To locate the 
coding regions within the 3.8-kb fragment, the entire frag- 
ment was sequenced and analyzed for putative open reading 
frames (ORFs). Sequence analysis revealed three ORFs that 
can encode for proteins larger than 100 amino acids in size. 
These three ORFs, designated ORF-A, ORF-B, and ORF-C, 
are shown in Fig. 5. ORF-A initiates at nucleotide 1032 and 
terminates at nucleotide 1805; its first methionine is located 
at nucleotide 1378, and it can potentially encode a protein of 
143 amino acids. ORF-B initiates at nucleotide 2069 and 
terminates at nucleotide 2399, and it encodes a protein of 110 
amino acids. ORF-C is a large ORF (366 amino acids) 
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FIG. 4. (A) Schematic diagram showing the Sall restriction sites 
which mapped to the pZVB70 fragment. (B) CAT activity in CV-1 
cells that were cotransfected with HIV-CAT and different SalI-cut 
subfragments of pZVB70. pZVB70 represents the intact plasmid, 
and the numbers indicate the size in kilobases of each pZVB70 DNA 
subfragment that was cotransfected with HIV-CAT. 
located on the opposite DNA strand. Its amino terminus is 
located outside the 3.8-kb fragment. Therefore, it is unlikely 
that ORF-C encodes a functional protein that is involved in 
trans activation observed with the 3.8-kb fragment. 
ORF-A is responsible for trans activation of the HIV LTR. 
To determine which ORF within the SalI 3.8-kb fragment is 
responsible for trans-activation activities, the 3.8-kb frag- 
ment was further characterized by restriction enzyme diges- 
tion and tested for HIV-CAT trans activation. One of the 
enzymes tested, AccI, eliminated ORF-B but not ORF-A, 
and the AccI-digested 3.8-kb fragment still retained trans- 
activation ability (data not shown). Thus, ORF-A may be 
responsible for the trans activation of the HIV LTR. To 
further confirm these results, both the 3.8-kb fragment and 
the 1.86-kb fragment containing ORF-A were subcloned and 
designated p3.8 and p1.86, respectively (Fig. 6). In addition, 
the ORF-A coding sequence was amplified by using the 
polymerase chain reaction, subcloned downstream of the 
Rous sarcoma virus (RSV) LTR, and designated pB701 (Fig. 
6). These subclones, p3.8, p1.86, and pB701, were cotrans- 
fected along with HIV-CAT into both CV-1 cells and human 
T cells (HSB-2) and tested for trans-activation activities. All 
plasmid constructs containing ORF-A were found to be 
BamH 1 ACC 1 
p1.86 
Sal 1 Hind Ill 
1.367 1.828 -
RSV pB701 
FIG. 6. Schematic diagram showing the map of plasmid pZVB70 
and its various subclones. The map of pZVB70 indicates where the 
SalI-cut sites are located. p3.8, p1.86, and pB701 represents the 
subclones of pZVB70. Both p3.8 and p1.86 were subcloned into 
pUC plasmids. pB701 was subcloned into a plasmid containing the 
Rous sarcoma virus (RSV) promoter. The stippled boxes represent 
ORF-A, and the open box represents ORF-B. 
active in both CV-1 cells and T cells (Fig. 7), indicating that 
ORF-A may indeed be the primary gene responsible for 
activation of the HIV promoter. It is of interest to note that 
in CV-1 cells (Fig. 7A), pB701, which uses Rous sarcoma 
virus LTR as a promoter, possesses lower trans-activating 
activity than does p1.86, which uses the endogenous HHV-6 
promoter. However, this difference was not significant in 
HSB-2 cells. In HSB-2 cells, the cloned plasmids always 
gave slightly lower trans-activation activities than did the 
intact pZVB70 (Fig. 7B). It is possible that a second gene in 
pZVB70 also participates in the trans activation of the HIV 
LTR in HSB-2 cells. Nevertheless, these results clearly 
demonstrate that ORF-A is one of the major HHV-6 gene 
products that trans activates the HIV LTR in both CV-1 and 
human T cells. This ORF was designated B701. Our se- 
quence analyses show that B701 encodes a protein of 143 
amino acids (Fig. 8). Two potential promoters with TATAA- 
like sequence are found at positions 5' of the first ATG, and 
a potential polyadenylation site is found at the 3' end (Fig. 
8). 
trans activation of HIV LTR by B701 also involves the 
NF-KB region. To further confirm that B701 functions in a 
similar fashion to the HHV-6 and pZVB70 fragments in trans 
activation of the HIV LTR, pB701 was cotransfected along 
with either the intact HIV promoter or the mutant NF-KB 
promoter in both CV-1 (Fig. 9A) and HSB-2 (Fig. 9B) cells. 
FIG. 5. Analysis for potential ORFs encoded by the 3.8-kb fragment of pZVB7O. The three identified ORFs larger than 100 amino acids 
are designated A, B, and C. 1, 2, and 3 represent reading frames in the first DNA strand; 4, 5, and 6 represent reading frames in the opposite 
strand. 
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FIG. 7. CAT assays of cells that were transfected with HIV-CAT 
alone or cotransfected with various subclones of pZVB70 (Fig. 6). 
(A) Transfection studies done in CV-1 cells; (B) studies done in T 
cells. 
As expected, trans activation was abolished when the 
NF-KB mutant promoter was used. Furthermore, trans 
activation of the intact HIV promoter in HSB-2 by pB701 is 
higher than the trans activation obtained with HHV-6 infec- 
tion (Fig. 9B). Together, these results suggest that the B701 
gene of HHV-6 encodes a protein which may be responsible 
for most of the trans-activating activity on the HIV promoter 
by HHV-6. 
DISCUSSION 
Activation of the HIV LTR by exogenous viral infections, 
such as by herpesviruses, is apparently a complex process. 
For HSV-1, at least two different immediate-early gene 
products, ICPO and ICP4, have been shown to enhance the 
expression of HIV LTR-CAT constructs (1). However, 
these stimulatory effects on the HIV LTR by cloned genomic 
HSV-1, ICPO, and ICP4 fragments varied with cell type (26), 
indicating that the cellular environment plays an important 
role in trans activation. Our study shows that trans activa- 
tion of the HIV-LTR by the HHV-6 gene fragment B701 in a 
nonlymphoid cell line (CV-1) was as effective as that ob- 
served in a human T-cell line (HSB-2). It is likely that these 
two cell lines involve similar cellular factors, such as NF-KB, 
in mediating the trans activation. Studies using a larger panel 
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FIG. 8. Nucleotide sequence and potential amino acid sequence 
of ORF-A (B701). Numbers above the nucleotide sequence repre- 
sent nucleotide numbers; those at the right represent amino acid 
numbers. The two potential TATA boxes found at the 5' end of the 
coding region, the termination codon TAA, and the potential poly- 
adenylated signal sequences are highlighted by boldface. 
of different cell types need to be carried out to further 
confirm these observations. 
Our transfection studies show that cloned B701 fragment 
activates the HIV LTR as effectively as does the entire 
22.25-kb pZVB70 fragment and that this activation is at least 
as effective as, if not better than, activation by HHV-6 
infection. These data suggest that B701 may indeed be the 
primary HHV-6 gene responsible for activation of HIV. 
Previous studies by Ensoli et al. (7) and us (13, 14) have 
demonstrated that activation of HIV by HHV-6 involves the 
LTR- Intact N F - k ~  
pB701 - + - + 
LTR" Intact N F - k ~  
GS - + -  - + -  
pB701 - - + - - 
FIG. 9. Transfection studies done in CV-1 cells (A) or T cells (B) 
with either intact HIV-CAT or mutant NF-KB CAT. Cells were 
transfected with HIV-CAT alone, cotransfected with HIV-CAT and 
pB701, or infected with HHV-6 (GS). Shown are counts obtained at 
5 h after initiation of the assay. 
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FIG. 10. Amino acid homology between the HHV-6 B701 ORF 
and the human cytomegalovirus (HCMV) US22 gene product. 
Amino acid comparison (ktup = 1) was performed by using the 
FASTA program of Lipman and Pearson (19). Identical amino acids 
are marked by two dots, and conservative changes are marked by 
single dot. 
NF-KB sites located in the HIV LTR. We have now demon- 
strated that trans activation of the HIV LTR by the cloned 
B701 gene also involves NF-KB target sites. The HIV LTR 
construct, with specific mutations in the NF-KB binding 
sites, completely lost its ability to be activated by B701. This 
finding is similar to results obtained with HHV-6 infection. 
This result further supports the theory that B701 may indeed 
be the major HHV-6 trans-activating gene segment. Involve- 
ment of NF-KB in activation of the HIV LTR by HHV-6 is 
much more specific than with other herpesviruses. As we 
have consistently observed, a single mutation in the NF-KB 
core binding sequences can completely eliminate the trans 
activation of the HIV LTR by HHV-6. For other trans- 
acting herpesviruses, such as HSV-1, in addition to the 
NF-KB sites, the Sp l  sites located on the HIV LTR also 
served as target sites of trans activation by HSV-1 (22). 
However, there may still be HHV-6 genes other than B701 
that can trans activate the HIV LTR but may or may not 
involve NF-KB as a target site. Further work is in progress to 
identify and characterize these genes. Nevertheless, the 
specific involvement of NF-KB in trans activation by B701 
provides a useful system with which to further study the 
mechanism of interaction between HIV and HHV-6. 
Sequence analyses show that B701 potentially encodes a 
protein of 143 amino acids. It is interesting to note that such 
a small herpesvirus protein has trans-acting potential. It is 
possible that the putative B701 protein is part of a larger gene 
product which is generated by splicing. Thus, the HHV-6 
trans-activating protein may actually be a larger protein 
whose functional domain is encoded by B701. The putative 
B701 protein shares no sequence homology with any other 
known proteins except that there is some weak homology 
with the cytomegalovirus early US22 gene family (5) (Fig. 
10). In one stretch of 72 amino acids, there is 29.1% identity 
between the US22 and B701 ORFs. Thus, it is likely that the 
putative B701 protein may also encode an early gene product 
which plays a role in the regulation of viral gene expression, 
similar to the ICPO and ICP4 genes of HSV (26). Studies are 
now in progress to identify and characterize the protein 
encoded by the B701 fragment. 
There are several possible mechanisms by which the 
putative B701 protein may function in trans activation of the 
HIV LTR. The B701 protein can bind directly to NF-KB 
target sites on the HIV LTR and activate its expression. 
Alternatively, the B701 protein can function indirectly via 
cellular intermediates, such as NF-KB or similar proteins. 
The B701 protein may activate expression of the genes 
encoding these cellular factors or may interact directly with 
these factors to enhance their activities. Thus, infection of 
target cells by HHV-6 may activate or elevate activities of 
cellular factors like NF-KB, which can subsequently activate 
HIV expression. It has indeed been demonstrated that 
HSV-1 infection of HeLa cells induces NF-KB activities 
which result in augmentation of HIV LTR expression (10). It 
is also tempting to speculate that HHV-6 may activate its 
own gene expression via cellular factors, such as NF-KB, 
which may be required for HHV-6 transcription. However, a 
DNA sequence homology search indicates that the putative 
B701 protein contains no obvious DNA-binding motifs or 
leucine zipper-like domains which function in protein-pro- 
tein interaction. Again, the exact mechanism(s) of B701 
protein action in regulation of HHV-6 or HIV gene expres- 
sion needs to be elucidated. 
The clinical significance of HHV-6 infection alone, or 
HHV-6 and HIV coinfection, remains to be determined. It is 
clear that both viruses can infect the same CD4+ target T 
cells and that coinfection augments HIV expression and 
cytopathic effects. The identification of an HHV-6 gene such 
as B701, and deciphering of the mechanisms by which it can 
activate HIV, may provide a target protein for the develop- 
ment of agents that can block potentiation of HIV by 
HHV-6. 
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